Stay updated with breaking news from Michael Vi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Swan assumed the role of interim CEO following the resignation of Brian Krzanich in June 2018 after Intel learned of a consensual relationship Krzanich had with an...
Myr GmbH, a company focused on developing therapies for the treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis. The acquisition brings Myr’s chronic HDV treatment Hepcludex (bulevirtide) under its umbrella. Hepcludex was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July. Hepcludex is an entry inhibitor that binds to NTCP, an essential HBV and HDV receptor on hepatocytes. It blocks the ability of HDV to enter hepatocytes. Hepcludex is currently the on...